ArticleRegenerative therapy2025
Cholangiocyte-derived exosomal miR-381-3p promotes hepatic stellate cell activation and cholestatic liver fibrosis via targeting Klf6.
Article in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Regulatory roles and translational potential of the Kruppel-like factor family in liver disease.iLIVER · 2026Review
- From network prediction to in vivo validation: luteolin attenuates cholestatic liver injury in association with PI3K/Akt/GSK-3β signalling modulation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The Role of Epigenetics in Corneal Fibrosis.Epigenomes · 2026Review
- miR-140-5p Inhibition alleviates LPS-induced cholangitis in rats and is associated with modulation of the NF-κB signaling pathway.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The activation of hepatic stellate cells (HSCs) is a central mechanism driving the progression of chronic cholestatic liver diseases (CCLD). MicroRNAs (miRNAs) have been increasingly recognized for their regulatory roles in various liver pathologies. This study aimed to identify specific miRNAs involved in the progression of CCLD and elucidate their underlying molecular mechanisms. Methods: A bile duct ligation (BDL) mouse model was established to mimic cholestatic liver injury. Exosomes were isolated from mouse large cholangiocytes (MLE) and co-cultured with HSCs to investigate their functional effects. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was employed to assess the expression levels of fibrotic marker genes. Exosomal miRNA microarray assay was used to screen differentially expressed miRNAs. Furthermore, dual-luciferase reporter assays and RNA pull-down experiments were conducted to validate the interaction between miR-381-3p and its putative target gene, kinesin family member 6 (Klf6). Results: The results confirmed the successful isolation of exosomes from MLE. Furthermore, exosomes derived from BDL-MLE were shown to promote the activation of HSCs and exacerbate hepatic fibrosis. Dicer knockout reduced the mRNA expression of key fibrotic markers. In addition, miR-381-3p was found to be upregulated both in BDL-MLE-derived exosomes and in HSCs treated with transforming growth factor (TGF)-β and BDL-MLE-exosomes. Mechanistic investigations identified Klf6 as a direct target gene of miR-381-3p. Rescue experiments further revealed that overexpression of Klf6 alleviated the pro-fibrotic effects caused by miR-381-3p overexpression, thereby attenuating HSC activation and mitigating cholestatic liver fibrosis. Conclusion: This study highlighted the role of MLE-derived exosomal miR-381-3p in promoting HSC activation and cholestatic liver fibrosis through the regulation of Klf6. These findings provide novel insights into the molecular mechanisms underlying CCLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.